Leonard van den Berg is professor of neurology and chairman of TRICALS. He is also director of The Netherlands ALS Center, which aims to improve the diagnosis, treatment/care and scientific research for ALS in the Netherlands. As chairman of the European Network to find the Cure for ALS (ENCALS), as initiator of the worldwide ALS genetics research Project MinE and as coordinator of awarded EU grants (FP7 Euro-MOTOR (systems biology) and JPND SOPHIA (biomarkers), he is strongly committed to international collaborations on ALS research.
He has been the principle investigator of multiple multicenter clinical trials and in 2015 he established the Treatment Research Initiative to Cure ALS to accelerate the search for a cure.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.